MADISON, Wis., April 8, 2020 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that the company plans to
release its first-quarter 2020 financial results after the close of
the U.S. financial markets on May 6,
2020. Following the release, company management will host a
webcast and conference call at 5 p.m.
ET to discuss financial results and business progress.
First-Quarter 2020 Webcast & Conference Call
Details
Date:
|
Wednesday, May 6,
2020
|
Time:
|
5 p.m. ET, 4 p.m.
CT
|
Webcast:
|
The live webcast can
be accessed at www.exactsciences.com
|
Telephone:
|
Domestic callers,
dial 833-235-7650
|
|
International
callers, dial +1 647-689-4171
|
|
Access code for both
domestic and international callers: 7874149
|
An archive of the webcast will be available at
www.exactsciences.com. A replay of the conference call will be
available by calling 800-585-8367 domestically or 416-621-4642
internationally. The access code for the replay of the call is
7874149. The webcast, conference call and replay are open to all
interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests,
Exact Sciences relentlessly pursues smarter solutions providing the
clarity to take life-changing action, earlier. Building on the
success of Cologuard and Oncotype DX, Exact Sciences is investing
in its product pipeline to take on some of the deadliest cancers
and improve patient care. Exact Sciences unites visionary
collaborators to help advance the fight against cancer. For more
information, please visit the company's website at
www.exactsciences.com, follow Exact Sciences on Twitter
@ExactSciences, or find Exact Sciences on Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
that are intended to be covered by the "safe harbor" created by
those sections. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies
and expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "would," "could," "seek," "intend," "plan," "goal,"
"project," "estimate," "anticipate" or other comparable
terms. All statements other than statements of historical
facts included in this news release regarding our strategies,
prospects, expectations, financial condition, operations, costs,
plans and objectives are forward-looking statements. Examples of
forward-looking statements include, among others, statements we
make regarding expected future operating results, anticipated
results of our sales, marketing and patient adherence efforts,
expectations concerning payer reimbursement and regulatory matters,
the anticipated results of our product development efforts and the
anticipated benefits of our combination with Genomic Health, Inc.,
including estimated synergies and other financial impacts.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: uncertainties associated with
COVID-19, including its possible effects on our operations and the
demand for our products and services; our ability to efficiently
and flexibly manage our business amid uncertainties related to
COVID-19; our ability to successfully and profitably market our
products and services; the acceptance of our products and services
by patients and healthcare providers; our ability to meet demand
for our products and services; the success of our efforts to
facilitate patient access to Cologuard via telehealth; the
willingness of health insurance companies and other payers to cover
our products and services and adequately reimburse us for such
products and services; the amount and nature of competition in the
cancer detection, treatment guidance and monitoring space; the
effects of the adoption, modification or repeal of any law, rule,
order, interpretation or policy relating to the healthcare system,
including without limitation as a result of any judicial, executive
or legislative action; the effects of changes in pricing, coverage
and reimbursement for our products and services, including without
limitation as a result of the Protecting Access to Medicare Act of
2014; recommendations, guidelines and quality metrics issued by
various organizations such as the U.S. Preventive Services Task
Force, the American Society of Clinical Oncology, the American
Cancer Society, and the National Committee for Quality Assurance
regarding cancer screening or our products and services; our
ability to successfully develop new products and services and
assess potential market opportunities; our ability to effectively
utilize strategic partnerships, such as through our Promotion
Agreement with Pfizer, Inc., and acquisitions; our success
establishing and maintaining collaborative, licensing and supplier
arrangements; our ability to maintain regulatory approvals and
comply with applicable regulations; our ability to manage an
international business and our expectations regarding our
international expansion and opportunities; the potential effects of
foreign currency exchange rate fluctuations and our efforts to
hedge such effects; the possibility that the anticipated benefits
from our combination with Genomic Health cannot be realized in full
or at all or may take longer to realize than expected; the
possibility that costs or difficulties related to the integration
of Genomic Health's operations will be greater than expected and
the possibility of disruptions to our business during integration
efforts and strain on management time and resources; the outcome of
any litigation, government investigations, enforcement actions or
other legal proceedings; and the other risks and uncertainties
described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections
of our most recently filed Annual Report on Form 10-K and our
subsequently filed Quarterly Reports on Form 10-Q. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Investor Relations Contact:
Megan Jones
Exact Sciences Corp.
meganjones@exactsciences.com
608-535-8815
View original content to download
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-schedules-first-quarter-2020-earnings-call-301037237.html
SOURCE EXACT SCIENCES CORP